Pharvaris NV
NASDAQ:PHVS
Pharvaris NV
NASDAQ:PHVS
Price:
26.135
USD
-2.48%
Market Cap:
$1.7B
Pharvaris NV
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Pharvaris NV
Business Overview
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
No Earnings Calls Available
Management
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Co-Founder, CEO & Executive Director
No Bio Available
Ms. Anna Nijdam M.Sc., R.A.
Head of Strategic Finance & Principal Accounting Officer
No Bio Available
Dr. Stefan Abele Ph.D.
Chief Technology Operations Officer
No Bio Available
Ms. Annick Deschoolmeester
Chief Human Resources Officer
No Bio Available
Dr. Peng Lu M.D., Ph.D.
Chief Medical Officer
No Bio Available
Dr. Anne A. Lesage Ph.D.
Chief Early Development Officer
No Bio Available
Mr. Wim Souverijns Ph.D.
Chief Commercial Officer
No Bio Available
Mr. David W. Nassif J.D.
CFO & Corporate Secretary
No Bio Available
Maryann Cimino
Director of Corporate Relations
No Bio Available
